Development and Discovery of a Selective Degrader of Casein Kinases 1 δ/ε
Journal of Medicinal Chemistry · 2025
DOI: 10.1021/acs.jmedchem.4c02201 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Medicinal Chemistry, 2025. Verfasst von Adrian Haag und 14 weiteren Autor:innen. Beteiligte Einrichtung: Institute of Pharmaceutical Chemistry, Goethe University, Max-von-Laue-Str. 9, 60438 Frankfurt am Main, Germany. Hauptthemen laut MEDLINE: Casein Kinase 1 epsilon, Casein Kinase Idelta, Proteolysis, Protein Kinase Inhibitors. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 38 Literaturangaben. Gefördert von: European Research Council, Deutsches Krebsforschungszentrum, Deutsche Forschungsgemeinschaft.
Abstract (Originalsprache)
Members of the casein kinase 1 (CK1) family have emerged as key regulators of cellular signaling and as potential drug targets. Functional annotation of the 7 human isoforms would benefit from isoform-selective inhibitors, allowing studies on the role of these enzymes in normal physiology and disease pathogenesis. However, due to significant sequence homology within the catalytic domain, isoform selectivity is difficult to achieve with conventional small molecules. Here, we used a PROTAC (Proteolysis TArgeting Chimeras) approach to develop a highly selective degrader AH078 (37) targeting CK1δ and CK1ε with excellent selectivity over the highly related CK1α isoform. The developed PROTAC, AH078 (37) selectively degraded CK1δ and CK1ε with a DC50 of 200 nM. Characterization of AH078 (37) revealed a VHL and Ubiquitin-dependent degradation mechanism. Thus, AH078 (37) represents a versatile chemical tool to study CK1δ and CK1ε function in cellular systems.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Institute of Pharmaceutical Chemistry, Goethe University, Max-von-Laue-Str. 9, 60438 Frankfurt am Main, Germany.
- Structural Genomics Consortium (SGC), Buchmann Institute for Life Sciences, Max-von-Laue-Str. 15, 60438 Frankfurt am Main, Germany.
- Department of Experimental Biology, Faculty of Science, Masaryk University, 625 00 Brno, Czech Republic.
- Institute of Biochemistry, University of Kiel, Rudolf-Höber-Str. 1, Kiel 24118, Germany.
- NEOsphere Biotechnologies GmbH, Fraunhoferstr. 1, 82152 Martinsried, Germany.
- German translational cancer network (DKTK) site Frankfurt Mainz, 60590 Heidelberg, Germany.
ORCID-Profile: Václav Němec, Martin P Schwalm, Stefan Knapp
Förderung
- European Research Council
- Deutsches Krebsforschungszentrum
- Deutsche Forschungsgemeinschaft
- Grantov? Agentura Cesk? Republiky
- Structural Genomics Consortium
- Innovative Health Initiative
- Deutsche Krebshilfe
- Frankfurt Cancer Institute
Zitieren
APA
Haag, A., Němec, V., Janovská, P., Bartošíková, J., Adhikari, B., Müller, J., Schwalm, M. P., Čada, Š., Ohmayer, U., Daub, H., Kim, Y., Born, F., Wolf, E., Bryja, V., & Knapp, S. (2025). Development and Discovery of a Selective Degrader of Casein Kinases 1 δ/ε. Journal of Medicinal Chemistry. https://doi.org/10.1021/acs.jmedchem.4c02201
Vancouver
Haag A, Němec V, Janovská P, Bartošíková J, Adhikari B, Müller J, et al. Development and Discovery of a Selective Degrader of Casein Kinases 1 δ/ε. Journal of Medicinal Chemistry. 2025. doi:10.1021/acs.jmedchem.4c02201
BibTeX
@article{Haag2025,
author = {Haag, Adrian and Němec, Václav and Janovská, Pavlína and Bartošíková, Jana and Adhikari, Bikash and Müller, Juliane and Schwalm, Martin P and Čada, Štěpán and Ohmayer, Uli and Daub, Henrik and Kim, Yeojin and Born, Florian and Wolf, Elmar and Bryja, Vítězslav and Knapp, Stefan},
title = {Development and Discovery of a Selective Degrader of Casein Kinases 1 δ/ε},
journal = {Journal of Medicinal Chemistry},
year = {2025},
doi = {10.1021/acs.jmedchem.4c02201}
}
EUVIMED